Long term human study proves Nicotinamide Riboside safely elevates NAD+

Preliminary results are in for this clinical study of 120 elderly subjects taking Elysium Health’s BASIS that was completed July 28.

Although the full results are not yet published, Elysium Health just issued this press release stating that primary and secondary endpoints were met.

Healthy patients between 60 and 80 years of age were given placebo,  or 2 different dosages of BASIS daily for 8 weeks.

BASIS is a combination of 2 products patented by Chromadex , Nicotinamide Riboside (NR) and Pterostilbene.

Note – this is not the same as NMN (Nicotinamide Mono-Nucleotide).

Those given BASIS received either a single capsule containing 250 mg Nicotinamide Riboside (NR), and 50 mg Pterostilbene, or 2 capsules, containing 500 mg NR and 100 mg Pterostilbene.

The full study can be found here:

A Study to Evaluate Safety and Health Benefits of Basis™ Among Elderly Subjects

Some of the findings noted in the press release were:

  • Study subjects showed no serious adverse events, confirming BASIS to be safe for use over extended periods
  • Subjects taking a single capsule with 250mg NR showed an average increase in blood NAD+ levels of 40% over baseline by week 4 and maintained that increase throughout the trial
  • Subjects taking 2 capsule with 500mg NR were found to have a 90% elevation in blood NAD+ levels at week 4, and maintained a significantly higher blood NAD+ level throughout the trial (compared to those taking a single capsule)
[box] Long term supplementation with NR is safe and effectively elevates NAD+ levels in Humans [/box]


dosageA previously published human study on NR supplemention effects on NAD+ levels used 100, 300, and 1,000mg dosages of NR.

Results from the 2 experiments in that prior study seemed to indicate the most effective dosage of NR as being somewhere between the 300 and 1,000mg levels.

Although details are scarce, the preliminary results from this most recent clinical study seem to agree with the prior study as to NR dosage effects on blood NAD+.

We note the press release says the higher dosage with 500mg of NR showed 90% increase in NAD+ over baseline at 4 weeks.

That 90% increase was not maintained throughout, but did show a “significant increase” throughout the study.

So, the blood NAD+ increase was higher at 4 weeks and came back down somewhat over the remaining 4 weeks the study. (testing was limited to 4 times throughout the study)

This seems to indicate that the maximum sustainable NAD+ increase thru NR supplementation is achieved with 500 mg a day, and any dosage higher than 500mg would probably not be more effective.

It’s quite possible that a dose lower than 500 mg that would achieve same increase in NAD+, but there is no clue from this study what that dose might be.

Note that these are averages and that individuals exhibit a wide variety of response to NR supplementation.

[box]On average, 500 mg day of NR appears to be sufficient to achieve maximum blood NAD+ elevation [/box]



Some things we find interesting about the study design:

  • Dosages of 250 and 500mg only. Implies they don’t believe more than 500mg is beneficial
  • Only 4 office visits during the testing, so not going to see daily NAD+ levels

Primary Outcomes

  • Basic health parameters to ensure safety – blood pressure, blood parameters, heart rate.  Should be no problem at these dosages, so expect press release soon saying they met primary endpoints

Secondary Outcomes

  • NAD+ measurements as expected
  • Interesting they include a lot of performance measurements – treadmill, chair standing, elderly activity testing.
  • Body Weight measurement – weight loss has been mentioned in some reports, but very little so far.  Could be a game changer if positive response


  • Pain Assessment.  Another benefit that has been mentioned very little in previous reports

Inclusion/Exclusion Criteria

  • Healthy individuals only
  • 60 to 80 years age – much older than the first study published on human testing.  Will be very interesting to see dosage and NAD+ response in this population
  • Bodyweight – 18-35kg per m2 – fairly limited upper weight is surprising – maybe limiting the potential for weight loss.


Primary Outcome Measures:









6 thoughts on “Long term human study proves Nicotinamide Riboside safely elevates NAD+

  1. Ronald Myers says:

    It is good to see that NAD+ is increased by taking Basis but we need to know if that means anything to our health. I would like to see the results of the metabolic and physical outcomes of taking Basis during the study. That’s where the rubber meets the road. Taking a year or more to get all data statistically analyzed, written up, sent out for peer review, and re-write based on those reviews can take more than a year, so I am not concerned about the time lag. We may find a wide range of effects or little or no effect on some of the criteria being measured. Also, the study may have been simply too short to see some of the outcomes we are hoping for. Let’s wait and see.

  2. John B says:

    After reading for over an hour about Basis…..articles talked me out of it. I am a scientist. If you got favorable information from your study, you would have IMMEDIATELY published it. Now you are trying to “spin” the study, or kill it. NOT GOOD.
    I have tried every supplement and prescription (Deplin) to help improve my life, they were all a waste of money and time.
    Stick with a balanced vitamin schedule, exercise and eat healthy. Then you don’t need a “fountain of youth” expensive capsules.

  3. Greg says:

    This says it all…”Although the full results are not yet published, Elysium Health just issued this press release”. The trial was completed July 2016. Nothing to see here but savvy marketing.

  4. Pierre says:

    I do take the supplement but now I am very concerned with the claims being made. The study quoted began Feb 3, 2016 and was completed July 2016 but yet the results are not published and we are at the end of May 2017. Have the researchers abandoned the trial? Were there unexpected or negative results? Did the early noted benefits disappear? So many questions to be ansered.
    Why would the researchers need a year to complete the study?

    Take a look yourself:

    No Study Results Posted on for this Study
    About Study Results Reporting on
    Study Status: This study has been completed.
    Study Completion Date: No date given
    Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)

  5. carmel says:

    Hi my name is Carmel I would be interested in doing a trial with this product as I have chronic fatigue and irritable bowel and stomach irritation , If that is for free I would be very interested to try it out as I am not working at the moment.

    Warm regards,


Leave a Reply

Your email address will not be published.